Skip to main content
Erschienen in: PharmacoEconomics 2/2001

01.12.2001 | Current Opinion

Using Health Outcomes Data to Inform Decision-Making

Healthcare Payer Perspective

verfasst von: Professor Pierre-Jean Lancry, Richard O’Connor, David Stempel, Meir Raz

Erschienen in: PharmacoEconomics | Sonderheft 2/2001

Einloggen, um Zugang zu erhalten

Abstract

Healthcare payers are charged with the responsibility of achieving maximum profits or output within their limited budget. As the demands are always greater than the budget, there is growing interest in tools that can inform decisions on the allocation of limited resources. Healthcare payers are using health outcomes data to assist the decision-making process, although the way in which such information is being used may differ between payers.
From the perspective of the French sickness fund, there is a need for real-world information to supplement the results of clinical trials and inform negotiations on pricing. In the US, the large databases of healthcare insurers are being examined in order to carry out retrospective cohort studies that go some way towards providing such real-world information on outcomes with alternative treatments. Another approach to health outcomes information has been taken by an Israeli healthcare organisation, Maccabi Healthcare Services, which introduced a disease management programme in order to improve outcomes of asthma management.
Clearly, healthcare payers are using health outcomes information in a variety of ways to inform decision-making. The extensive databases available to payers may be used to good effect, to obtain real-life information that supplements clinical trial data and economic models of outcomes and costs, and to enable the targeting of interventions.
Literatur
1.
2.
Zurück zum Zitat Lancry P-J. Médicaments: approche économique et institutionnelle. Paris: Caisse Nationale de l’AssuranceMaladie des Travailleurs Salariés, Jun 2000 Lancry P-J. Médicaments: approche économique et institutionnelle. Paris: Caisse Nationale de l’AssuranceMaladie des Travailleurs Salariés, Jun 2000
3.
Zurück zum Zitat MEDICAM. Les médicaments remboursés par le Régime Général d’Assurance Maladie au cours des années 1999 et 2000. Paris: Caisse Nationale de l’Assurance Maladie des Travailleurs Salariés, Apr 2001 MEDICAM. Les médicaments remboursés par le Régime Général d’Assurance Maladie au cours des années 1999 et 2000. Paris: Caisse Nationale de l’Assurance Maladie des Travailleurs Salariés, Apr 2001
4.
Zurück zum Zitat Comité Economique des Produits de Santé (CEPS). Rapport d’activité 2000. Paris: CEPS, Jun 2001 Comité Economique des Produits de Santé (CEPS). Rapport d’activité 2000. Paris: CEPS, Jun 2001
5.
Zurück zum Zitat Xiaofeng L, Larinpour R, Sennett C, et al. Improving the treatment of patients with asthma: characteristics of patients with severely symptomatic disease. J Eval Clin Practice 2001. In press Xiaofeng L, Larinpour R, Sennett C, et al. Improving the treatment of patients with asthma: characteristics of patients with severely symptomatic disease. J Eval Clin Practice 2001. In press
6.
Zurück zum Zitat O’Connor RD, Wang SW, Pinto LA, et al. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Ann Allergy Asthma Immunol 2001; 86: 81 O’Connor RD, Wang SW, Pinto LA, et al. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Ann Allergy Asthma Immunol 2001; 86: 81
7.
Zurück zum Zitat Ollendorf DA, Pozniak AS, Bowers BB, et al. Economic impact of salmeterol versus leukotriene modifiers in patients with chronic asthma [abstract no. 219]. Chest 2000; 118 Suppl.: 1855 Ollendorf DA, Pozniak AS, Bowers BB, et al. Economic impact of salmeterol versus leukotriene modifiers in patients with chronic asthma [abstract no. 219]. Chest 2000; 118 Suppl.: 1855
8.
Zurück zum Zitat Gothard LR, O’Donnell JC, Capuano GA, et al. Cost consequences of dual controller therapy for asthma: inhaled corticosteroids used concurrently with either salmeterol or leukotriene modifiers [abstract]. J Managed Care Pharm 2000; 6: 358 Gothard LR, O’Donnell JC, Capuano GA, et al. Cost consequences of dual controller therapy for asthma: inhaled corticosteroids used concurrently with either salmeterol or leukotriene modifiers [abstract]. J Managed Care Pharm 2000; 6: 358
9.
Zurück zum Zitat Stempel DA, Mayer JW, O’Donnell JC. The combination of salmeterol and fluticasone improves asthma-related health outcomes at lower cost compared to the combination of inhaled corticosteroids and montelukast [abstract]. J Allergy Clin Immunol 2001; 107 Pt 2: S101 Stempel DA, Mayer JW, O’Donnell JC. The combination of salmeterol and fluticasone improves asthma-related health outcomes at lower cost compared to the combination of inhaled corticosteroids and montelukast [abstract]. J Allergy Clin Immunol 2001; 107 Pt 2: S101
10.
Zurück zum Zitat Price DB, Maier WC, Price MJ, et al. Decline in health care use associated with concurrent use of salmeterol and fluticasone propionate. Am J Respir Crit Care Med 2000; 161 (3): A197 Price DB, Maier WC, Price MJ, et al. Decline in health care use associated with concurrent use of salmeterol and fluticasone propionate. Am J Respir Crit Care Med 2000; 161 (3): A197
Metadaten
Titel
Using Health Outcomes Data to Inform Decision-Making
Healthcare Payer Perspective
verfasst von
Professor Pierre-Jean Lancry
Richard O’Connor
David Stempel
Meir Raz
Publikationsdatum
01.12.2001
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe Sonderheft 2/2001
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200119002-00007

Weitere Artikel der Sonderheft 2/2001

PharmacoEconomics 2/2001 Zur Ausgabe